Michael Severino, M.D. has been named executive vice president, R&D and chief scientific officer at AbbVie. Dr. Severino will be responsible for leading the R&D, Medical Affairs and Regulatory Affairs organizations. He brings expertise from his career spanning genomics and development within the biotech industry.
Dr. Severino most recently served as senior vice president and chief medical officer at Amgen, leading the clinical development strategy across inflammation/immunology, neuroscience, oncology and cardiovascular disease, among other areas. In his ten years with the company, he held numerous roles of increasing responsibility across R&D. Prior to Amgen, Dr. Severino held positions in biologics and genomics research at Merck.
"AbbVie is pleased to welcome Dr. Severino to our new company," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "We are fortunate to have a leader of his caliber to steer our efforts to develop treatments for today's toughest health challenges. He will be instrumental in moving our pipeline and strategy forward."